Scenic Biotech Raises $31M in Series A Financing
Summary
The company intends to use the funds to accelerate the transition into a development stage company, advancing its in-house pipeline and supporting the creation of new programs based on its Cell-Seq genetic modifier target discovery platform including new industry collaborations. Led by CEO Oscar Izeboud, Scenic Biotech is focused on identifying genetic modifiers, a completely new class of disease targets, for drug intervention. Also known as disease suppressors, genetic modifiers are genes that act to suppress or completely block the effect of a disease-causing mutated gene.As a pioneer in the field, Scenic Biotech is leveraging its Cell-Seq discovery platform to identify genetic modifiers across multiple therapeutic areas. Alongside its in-house pipeline, Scenic has a multi-year, multi-indication strategic collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialize novel therapeutics that target genetic modifiers. The company anticipates more than doubling its team in the coming 18 months including building its clinical capabilities.